{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:25:14Z","timestamp":1787883914130,"version":"build-2784847793"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03000-z","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T05:19:04Z","timestamp":1761369544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cyclooxygenase-2 as a potential therapeutic target in the treatment of chemoresistant glioblastomas"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3417-2359","authenticated-orcid":false,"given":"Vladislav S.","family":"Skossyrskiy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2206-9584","authenticated-orcid":false,"given":"Natalya A.","family":"Kurdina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4086-7089","authenticated-orcid":false,"given":"Viktoriya S.","family":"Kuzovkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8468-2106","authenticated-orcid":false,"given":"Maxim S.","family":"Boot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9491-318X","authenticated-orcid":false,"given":"Polina I.","family":"Zelenchenkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1879-3000","authenticated-orcid":false,"given":"Ekaterina O.","family":"Popova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5841-7480","authenticated-orcid":false,"given":"Nadezhda V.","family":"Sevyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4125-7342","authenticated-orcid":false,"given":"Alexey A.","family":"Mitrofanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8880-1758","authenticated-orcid":false,"given":"Evgeniy V.","family":"Prozorenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1684-8781","authenticated-orcid":false,"given":"Marina I.","family":"Sekacheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0015-7094","authenticated-orcid":false,"given":"Ekaterina V.","family":"Orlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"3000_CR1","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/biomedicines9030324","volume":"9","author":"JP Fisher","year":"2021","unstructured":"Fisher JP, Adamson DC. Current FDA-approved therapies for high-grade malignant gliomas. Biomedicines. 2021;9:324. https:\/\/doi.org\/10.3390\/biomedicines9030324.","journal-title":"Biomedicines."},{"key":"3000_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","volume":"25","author":"A Omuro","year":"2023","unstructured":"Omuro A, Brandes AA, Carpentier AF, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro Oncol. 2023;25:123\u201334. https:\/\/doi.org\/10.1093\/neuonc\/noac099.","journal-title":"Neuro. Oncol."},{"key":"3000_CR3","doi-asserted-by":"publisher","first-page":"e043208","DOI":"10.1136\/bmjopen-2020-043208","volume":"11","author":"LS Bjorland","year":"2021","unstructured":"Bjorland LS, Fluge O, Gilje B, et al. Treatment approach and survival from glioblastoma: results from a population-based retrospective cohort study from Western Norway. BMJ Open. 2021;11:e043208. https:\/\/doi.org\/10.1136\/bmjopen-2020-043208.","journal-title":"BMJ. Open."},{"key":"3000_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.17161\/kjm.v12i3.11795","volume":"12","author":"DA Jaoude","year":"2019","unstructured":"Jaoude DA, Moore JA, Moore MB, et al. Glioblastoma and increased survival with longer chemotherapy duration. Kans J Med. 2019;12:65\u20139.","journal-title":"Kans. J. Med."},{"key":"3000_CR5","doi-asserted-by":"publisher","unstructured":"Stupp R, Brada M, van den Bent MJ, et al 2014. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals. Oncol. 25:iii93\u2013iii101. https:\/\/doi.org\/10.1093\/annonc\/mdu050","DOI":"10.1093\/annonc\/mdu050"},{"key":"3000_CR6","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1152\/physiolgenomics.00086.2017","volume":"49","author":"A Alexanian","year":"2017","unstructured":"Alexanian A, Sorokin A. Cyclooxygenase 2: protein-protein interactions and posttranslational modifications. Physiol Genomics. 2017;49:667\u201381. https:\/\/doi.org\/10.1152\/physiolgenomics.00086.2017.","journal-title":"Physiol. Genomics."},{"issue":"2","key":"3000_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/febs.16609","volume":"290","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zhou L, Lv C, et al. &lt;scp&gt;PGE2&lt;\/scp&gt; pathway mediates oxidative stress\u2010induced ferroptosis in renal tubular epithelial cells. FEBS J. 2023;290(2):533\u201349. https:\/\/doi.org\/10.1111\/febs.16609.","journal-title":"FEBS. J."},{"key":"3000_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bbalip.2014.07.008","volume":"1851","author":"K Kawahara","year":"2015","unstructured":"Kawahara K, Hohjoh H, Inazumi T, et al. Prostaglandin E2-induced inflammation: relevance of prostaglandin E receptors. Biochimica Et Biophysica Acta (BBA) \u2013 Molecular Cell Biology Lipid. 2015;1851:414\u201321. https:\/\/doi.org\/10.1016\/j.bbalip.2014.07.008.","journal-title":"Biochimica. Et. Biophysica. Acta. (BBA). \u2013 Molecular. Cell. Biology. Lipid."},{"key":"3000_CR9","doi-asserted-by":"publisher","first-page":"11613","DOI":"10.1074\/jbc.R600038200","volume":"282","author":"Y Sugimoto","year":"2007","unstructured":"Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem. 2007;282:11613\u20137. https:\/\/doi.org\/10.1074\/jbc.R600038200.","journal-title":"J. Biol. Chem."},{"key":"3000_CR10","doi-asserted-by":"publisher","first-page":"8037","DOI":"10.1158\/1078-0432.CCR-04-1208","volume":"10","author":"DS Dandekar","year":"2004","unstructured":"Dandekar DS, Lokeshwar BL. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Clin Cancer Res. 2004;10:8037\u201347. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1208.","journal-title":"Clin. Cancer. Res."},{"key":"3000_CR11","first-page":"1326","volume":"60","author":"K Kishi","year":"2000","unstructured":"Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 2000;60:1326\u201331.","journal-title":"Cancer. Res."},{"key":"3000_CR12","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.1002\/jcp.27411","volume":"234","author":"N Hashemi Goradel","year":"2019","unstructured":"Hashemi Goradel N, Najafi M, Salehi E, et al. Cyclooxygenase-2 in cancer: a review. J Cell Physiol. 2019;234:5683\u201399. https:\/\/doi.org\/10.1002\/jcp.27411.","journal-title":"J. Cell. Physiol."},{"key":"3000_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00819","author":"MM Ching","year":"2020","unstructured":"Ching MM, Reader J, Fulton AM. Eicosanoids in cancer: prostaglandin E2 receptor 4 in cancer therapeutics and immunotherapy. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.00819.","journal-title":"Front. Pharmacol."},{"key":"3000_CR14","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1021\/acs.analchem.7b05337","volume":"90","author":"B Gurram","year":"2018","unstructured":"Gurram B, Zhang S, Li M, et al. Celecoxib conjugated fluorescent probe for identification and discrimination of cyclooxygenase-2 enzyme in cancer cells. Anal Chem. 2018;90:5187\u201393. https:\/\/doi.org\/10.1021\/acs.analchem.7b05337.","journal-title":"Anal. Chem."},{"key":"3000_CR15","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1073\/pnas.94.7.3336","volume":"94","author":"M Tsujii","year":"1997","unstructured":"Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA. 1997;94:3336\u201340. https:\/\/doi.org\/10.1073\/pnas.94.7.3336.","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"3000_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1158\/1541-7786.MCR-07-0010","volume":"5","author":"I Stasinopoulos","year":"2007","unstructured":"Stasinopoulos I, O\u2019Brien DR, Wildes F, et al. Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol Cancer Res. 2007;5:435\u201342. https:\/\/doi.org\/10.1158\/1541-7786.MCR-07-0010.","journal-title":"Mol. Cancer. Res."},{"key":"3000_CR17","first-page":"1410","volume":"7","author":"SH Bae","year":"2001","unstructured":"Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-3981. Clin Cancer Res. 2001;7:1410\u20138.","journal-title":"Clin. Cancer. Res."},{"key":"3000_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1177604","author":"A Zhang","year":"2023","unstructured":"Zhang A, Zou X, Yang S, et al. Effect of NETs\/COX-2 pathway on immune microenvironment and metastasis in gastric cancer. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1177604.","journal-title":"Front. Immunol."},{"key":"3000_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1080\/07357900801941860","volume":"26","author":"P Gu","year":"2008","unstructured":"Gu P, Su Y, Guo S, et al. Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k\/Akt activation. Cancer Invest. 2008;26:822\u20139. https:\/\/doi.org\/10.1080\/07357900801941860.","journal-title":"Cancer. Invest."},{"key":"3000_CR20","doi-asserted-by":"publisher","first-page":"21268","DOI":"10.18632\/aging.203443","volume":"13","author":"D Yin","year":"2021","unstructured":"Yin D, Jin G, He H, et al. Celecoxib reverses the glioblastoma chemo-resistance to temozolomide through mitochondrial metabolism. Aging. 2021;13:21268\u201382. https:\/\/doi.org\/10.18632\/aging.203443.","journal-title":"Aging."},{"key":"3000_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1053\/j.seminoncol.2004.03.042","volume":"31","author":"B Arun","year":"2004","unstructured":"Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol. 2004;31:22\u20139. https:\/\/doi.org\/10.1053\/j.seminoncol.2004.03.042.","journal-title":"Semin. Oncol."},{"key":"3000_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1023\/A:1025863029529","volume":"23","author":"FA Sinicrope","year":"2004","unstructured":"Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev. 2004;23:63\u201375. https:\/\/doi.org\/10.1023\/A:1025863029529.","journal-title":"Cancer. Metastasis. Rev."},{"key":"3000_CR23","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3390\/ijms23031545","volume":"23","author":"F Lombardi","year":"2022","unstructured":"Lombardi F, Augello FR, Artone S, et al. Up-regulation of cyclooxygenase-2 (COX-2) expression by temozolomide (TMZ) in human glioblastoma (GBM) cell lines. Int J Mol Sci. 2022;23:1545. https:\/\/doi.org\/10.3390\/ijms23031545.","journal-title":"Int. J. Mol. Sci."},{"key":"3000_CR24","first-page":"4926","volume":"60","author":"T Joki","year":"2000","unstructured":"Joki T, Heese O, Nikas DC, et al. Expression of Cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-3981. Cancer Res. 2000;60:4926\u201331.","journal-title":"Cancer. Res."},{"key":"3000_CR25","first-page":"4375","volume":"61","author":"T Shono","year":"2001","unstructured":"Shono T, Tofilon PJ, Bruner JM, et al. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations1. Cance.r Res. 2001;61:4375\u201381.","journal-title":"Cance.r Res."},{"key":"3000_CR26","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/neuonc\/now049","volume":"18","author":"PJ Cook","year":"2016","unstructured":"Cook PJ, Thomas R, Kingsley PJ, et al. Cox-2-derived PGE 2 induces Id1-dependent radiation resistance and self-renewal in experimental glioblastoma. Neuro Oncol. 2016;18:1379\u201389. https:\/\/doi.org\/10.1093\/neuonc\/now049.","journal-title":"Neuro. Oncol."},{"key":"3000_CR27","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/sj.embor.7400755","volume":"7","author":"S Nishimoto","year":"2006","unstructured":"Nishimoto S, Nishida E. MAPK signalling: ERK5 versus ERK1\/2. EMBO Rep. 2006;7:782\u20136. https:\/\/doi.org\/10.1038\/sj.embor.7400755.","journal-title":"EMBO. Rep."},{"key":"3000_CR28","doi-asserted-by":"publisher","first-page":"8197","DOI":"10.2147\/OTT.S263977","volume":"13","author":"J Yang","year":"2020","unstructured":"Yang J, Wang X, Gao Y, et al. <p>Inhibition of PI3K-AKT Signaling Blocks PGE2-Induced COX-2 expression in lung adenocarcinoma<\/p>. Onco Targets Ther. 2020;13:8197\u2013208. https:\/\/doi.org\/10.2147\/OTT.S263977.","journal-title":"Onco. Targets. Ther."},{"key":"3000_CR29","doi-asserted-by":"publisher","first-page":"39672","DOI":"10.1074\/jbc.M110.117689","volume":"285","author":"K-S Chun","year":"2010","unstructured":"Chun K-S, Lao H-C, Langenbach R. The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and \u03b2-arrestin1-dependent signaling pathways. J Biol Chem. 2010;285:39672\u201381. https:\/\/doi.org\/10.1074\/jbc.M110.117689.","journal-title":"J. Biol. Chem."},{"key":"3000_CR30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.tips.2013.05.003","volume":"34","author":"J Jiang","year":"2013","unstructured":"Jiang J, Dingledine R. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Trends Pharmacol Sci. 2013;34:413\u201323. https:\/\/doi.org\/10.1016\/j.tips.2013.05.003.","journal-title":"Trends. Pharmacol. Sci."},{"issue":"S6","key":"3000_CR31","doi-asserted-by":"publisher","first-page":"S1073\u2013S1077","DOI":"10.21037\/tcr.2016.11.20","volume":"5","author":"L Oliver","year":"2016","unstructured":"Oliver L, Olivier C, Vallette FM. Prostaglandin E2 plays a major role in glioma resistance and progression. Transl Cancer Res. 2016;5(S6):S1073\u20137. https:\/\/doi.org\/10.21037\/tcr.2016.11.20.","journal-title":"Transl. Cancer. Res."},{"key":"3000_CR32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/jcp.22366","volume":"226","author":"SP Yun","year":"2011","unstructured":"Yun SP, Ryu JM, Jang MW, Han HJ. Interaction of profilin-1 and F-actin via a \u03b2-arrestin-1\/JNK signaling pathway involved in prostaglandin E 2 -induced human mesenchymal stem cells migration and proliferation. J Cell Physiol. 2011;226:559\u201371. https:\/\/doi.org\/10.1002\/jcp.22366.","journal-title":"J. Cell. Physiol."},{"key":"3000_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejphar.2017.05.064","volume":"810","author":"DA Chistiakov","year":"2017","unstructured":"Chistiakov DA, Chekhonin IV, Chekhonin VP. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme. Eur J Pharmacol. 2017;810:70\u201382. https:\/\/doi.org\/10.1016\/j.ejphar.2017.05.064.","journal-title":"Eur. J. Pharmacol."},{"key":"3000_CR34","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1038\/s41388-023-02796-2","volume":"42","author":"S Wan","year":"2023","unstructured":"Wan S, Liu C, Li C, et al. AKIP1 accelerates glioblastoma progression through stabilizing EGFR expression. Oncogene. 2023;42:2905\u201318. https:\/\/doi.org\/10.1038\/s41388-023-02796-2.","journal-title":"Oncogene."},{"key":"3000_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11060-020-03602-9","volume":"149","author":"Z Tang","year":"2020","unstructured":"Tang Z, Yang G, Wang X, et al. AKT\/GSK-3\u03b2\/\u03b2-catenin signaling pathway participates in erythropoietin-promoted glioma proliferation. J Neurooncol. 2020;149:231\u201342. https:\/\/doi.org\/10.1007\/s11060-020-03602-9.","journal-title":"J. Neurooncol."},{"key":"3000_CR36","doi-asserted-by":"publisher","first-page":"43016","DOI":"10.18632\/oncotarget.5513","volume":"6","author":"LF Leal","year":"2015","unstructured":"Leal LF, Bueno AC, Gomes DC, et al. Inhibition of the Tcf\/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis. Oncotarget. 2015;6:43016\u201332. https:\/\/doi.org\/10.18632\/oncotarget.5513.","journal-title":"Oncotarget."},{"key":"3000_CR37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191115","author":"L Du","year":"2020","unstructured":"Du L, Lee J-H, Jiang H, et al. \u03b2-catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. J Exp Med. 2020. https:\/\/doi.org\/10.1084\/jem.20191115.","journal-title":"J. Exp. Med."},{"key":"3000_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J, et al. Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7:3. https:\/\/doi.org\/10.1038\/s41392-021-00762-6.","journal-title":"Signal. Transduct. Target Ther."},{"key":"3000_CR39","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41389-017-0004-8","volume":"6","author":"J Langhans","year":"2017","unstructured":"Langhans J, Schneele L, Trenkler N, et al. The effects of PI3K-mediated signalling on glioblastoma cell behaviour. Oncogenesis. 2017;6:398. https:\/\/doi.org\/10.1038\/s41389-017-0004-8.","journal-title":"Oncogenesis."},{"key":"3000_CR40","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/ijms23031353","volume":"23","author":"A Barzegar Behrooz","year":"2022","unstructured":"Barzegar Behrooz A, Talaie Z, Jusheghani F, et al. Wnt and PI3K\/Akt\/mTOR survival pathways as therapeutic targets in glioblastoma. Int J Mol Sci. 2022;23:1353. https:\/\/doi.org\/10.3390\/ijms23031353.","journal-title":"Int. J. Mol. Sci."},{"key":"3000_CR41","doi-asserted-by":"publisher","unstructured":"Italiani P, Boraschi D 2014. From Monocytes to M1\/M2 Macrophages: Phenotypical vs. Functional Differentiation. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2014.00514","DOI":"10.3389\/fimmu.2014.00514"},{"key":"3000_CR42","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12935-021-02089-2","volume":"21","author":"J Liu","year":"2021","unstructured":"Liu J, Geng X, Hou J, Wu G. New insights into M1\/M2 macrophages: key modulators in cancer progression. Cancer Cell Int. 2021;21:389. https:\/\/doi.org\/10.1186\/s12935-021-02089-2.","journal-title":"Cancer. Cell. Int."},{"key":"3000_CR43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40478-021-01156-z","volume":"9","author":"A Buonfiglioli","year":"2021","unstructured":"Buonfiglioli A, Hambardzumyan D. Macrophages and microglia: the cerberus of glioblastoma. Acta Neuropathol Commun. 2021;9:54. https:\/\/doi.org\/10.1186\/s40478-021-01156-z.","journal-title":"Acta. Neuropathol. Commun."},{"key":"3000_CR44","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jds.2021.08.012","volume":"17","author":"W Katagiri","year":"2022","unstructured":"Katagiri W, Takeuchi R, Saito N, et al. Migration and phenotype switching of macrophages at early-phase of bone-formation by secretomes from bone marrow derived mesenchymal stem cells using rat calvaria bone defect model. J Dent Sci. 2022;17:421\u20139. https:\/\/doi.org\/10.1016\/j.jds.2021.08.012.","journal-title":"J. Dent. Sci."},{"key":"3000_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.20538\/1682-0363-2018-1-167-176","volume":"17","author":"EYa Shevela","year":"2018","unstructured":"Shevela EYa, Sakhno LV, Tikhonova MA, et al. Effects of mesenchymal stromal cells on monocyte differentiation to M1 phenotype and M1\/M2 macrophage switching. Bull Sib Med. 2018;17:167\u201376. https:\/\/doi.org\/10.20538\/1682-0363-2018-1-167-176.","journal-title":"Bull. Sib. Med."},{"key":"3000_CR46","doi-asserted-by":"publisher","first-page":"83976","DOI":"10.18632\/oncotarget.6930","volume":"7","author":"X Rong","year":"2016","unstructured":"Rong X, Huang B, Qiu S, et al. Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation. Oncotarget. 2016;7:83976\u201386. https:\/\/doi.org\/10.18632\/oncotarget.6930.","journal-title":"Oncotarget."},{"key":"3000_CR47","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ncb3090","volume":"17","author":"W Zhou","year":"2015","unstructured":"Zhou W, Ke SQ, Huang Z, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015;17:170\u201382. https:\/\/doi.org\/10.1038\/ncb3090.","journal-title":"Nat. Cell. Biol."},{"key":"3000_CR48","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00262-019-02423-8","volume":"68","author":"A Vidyarthi","year":"2019","unstructured":"Vidyarthi A, Agnihotri T, Khan N, et al. Predominance of M2 macrophages in gliomas leads to the suppression of local and systemic immunity. Cancer Immunol Immunother. 2019;68:1995\u20132004. https:\/\/doi.org\/10.1007\/s00262-019-02423-8.","journal-title":"Cancer. Immunol. Immunother."},{"key":"3000_CR49","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1038\/s41467-020-16789-2","volume":"11","author":"J Yin","year":"2020","unstructured":"Yin J, Kim SS, Choi E, et al. ARS2\/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages. Nat Commun. 2020;11:2978. https:\/\/doi.org\/10.1038\/s41467-020-16789-2.","journal-title":"Nat. Commun."},{"key":"3000_CR50","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/neuonc\/nos116","volume":"14","author":"W Li","year":"2012","unstructured":"Li W, Graeber MB. The molecular profile of microglia under the influence of glioma. Neuro Oncol. 2012;14:958\u201378. https:\/\/doi.org\/10.1093\/neuonc\/nos116.","journal-title":"Neuro. Oncol."},{"key":"3000_CR51","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.4049\/jimmunol.173.7.4352","volume":"173","author":"Y Akasaki","year":"2004","unstructured":"Akasaki Y, Liu G, Chung NHC, et al. Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol. 2004;173:4352\u20139. https:\/\/doi.org\/10.4049\/jimmunol.173.7.4352.","journal-title":"J. Immunol."},{"key":"3000_CR52","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4049\/jimmunol.1103248","volume":"189","author":"X Ye","year":"2012","unstructured":"Ye X, Xu S, Xin Y, et al. Tumor-associated microglia\/macrophages enhance the invasion of glioma stem-like cells via TGF-\u03b21 signaling pathway. J Immunol. 2012;189:444\u201353. https:\/\/doi.org\/10.4049\/jimmunol.1103248.","journal-title":"J. Immunol."},{"key":"3000_CR53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, Li Y, Zhang S, et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22:48. https:\/\/doi.org\/10.1186\/s12943-023-01744-8.","journal-title":"Mol. Cancer."},{"key":"3000_CR54","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/978-3-030-30845-2_13","volume-title":"Cancer immunology","author":"LP Garo","year":"2020","unstructured":"Garo LP, Gopal M. Role of cytokines in tumor immunity and immune tolerance to cancer. In: Cancer immunology. Heidelberg: Springer International Publishing; 2020. p. 205\u201333."},{"key":"3000_CR55","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1038\/sj.onc.1205894","volume":"21","author":"SS Lakka","year":"2002","unstructured":"Lakka SS, Rajan M, Gondi C, et al. Retracted article: Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene. 2002;21:8011\u20139. https:\/\/doi.org\/10.1038\/sj.onc.1205894.","journal-title":"Oncogene."},{"key":"3000_CR56","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12883-021-02477-1","volume":"21","author":"J Han","year":"2021","unstructured":"Han J, Jing Y, Han F, Sun P. Comprehensive analysis of expression, prognosis and immune infiltration for TIMPs in glioblastoma. BMC Neurol. 2021;21:447. https:\/\/doi.org\/10.1186\/s12883-021-02477-1.","journal-title":"BMC. Neurol."},{"key":"3000_CR57","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.3390\/cancers14071847","volume":"14","author":"K Augoff","year":"2022","unstructured":"Augoff K, Hryniewicz-Jankowska A, Tabola R, Stach K. MMP9: a tough target for targeted therapy for cancer. Cancers. 2022;14:1847. https:\/\/doi.org\/10.3390\/cancers14071847.","journal-title":"Cancers."},{"key":"3000_CR58","first-page":"551","volume":"9","author":"JE Rundhaug","year":"2003","unstructured":"Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00\u201300, 2003. Clin Cancer Res. 2003;9:551\u20134.","journal-title":"Clin. Cancer. Res."},{"key":"3000_CR59","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.3934\/mbe.2019164","volume":"16","author":"S Tariq Ashraf","year":"2019","unstructured":"Tariq Ashraf S, Obaid A, Tariq Saeed M, et al. Formal model of the interplay between TGF-\u03b21 and MMP-9 and their dynamics in hepatocellular carcinoma. Math Biosci Eng. 2019;16:3285\u2013310. https:\/\/doi.org\/10.3934\/mbe.2019164.","journal-title":"Math. Biosci. Eng."},{"key":"3000_CR60","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41419-022-04788-8","volume":"13","author":"T Yan","year":"2022","unstructured":"Yan T, Tan Y, Deng G, et al. TGF-\u03b2 induces GBM mesenchymal transition through upregulation of CLDN4 and nuclear translocation to activate TNF-\u03b1\/NF-\u03baB signal pathway. Cell Death Dis. 2022;13:339. https:\/\/doi.org\/10.1038\/s41419-022-04788-8.","journal-title":"Cell. Death. Dis."},{"key":"3000_CR61","doi-asserted-by":"publisher","first-page":"14341","DOI":"10.1038\/s41598-024-65398-2","volume":"14","author":"HD Thanh","year":"2024","unstructured":"Thanh HD, Lee S, Nguyen TT, et al. Temozolomide promotes matrix metalloproteinase 9 expression through p38 MAPK and JNK pathways in glioblastoma cells. Sci Rep. 2024;14:14341. https:\/\/doi.org\/10.1038\/s41598-024-65398-2.","journal-title":"Sci. Rep."},{"key":"3000_CR62","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/ana.10679","volume":"54","author":"M Platten","year":"2003","unstructured":"Platten M, Kretz A, Naumann U, et al. Monocyte chemoattractant protein\u20131 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol. 2003;54:388\u201392. https:\/\/doi.org\/10.1002\/ana.10679.","journal-title":"Ann. Neurol."},{"key":"3000_CR63","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1042\/BJ20090420","volume":"422","author":"G Zahner","year":"2009","unstructured":"Zahner G, Schaper M, Panzer U, et al. Prostaglandin EP2 and EP4 receptors modulate expression of the chemokine CCL2 (MCP-1) in response to LPS-induced renal glomerular inflammation. Biochem J. 2009;422:563\u201370. https:\/\/doi.org\/10.1042\/BJ20090420.","journal-title":"Biochem. J."},{"key":"3000_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964898","author":"G Wang","year":"2022","unstructured":"Wang G, Zhong K, Wang Z, et al. Tumor-associated microglia and macrophages in glioblastoma: from basic insights to therapeutic opportunities. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.964898.","journal-title":"Front. Immunol."},{"key":"3000_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.722916","author":"J Jin","year":"2021","unstructured":"Jin J, Lin J, Xu A, et al. CCL2: an important mediator between tumor cells and host cells in tumor microenvironment. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.722916.","journal-title":"Front. Oncol."},{"key":"3000_CR66","doi-asserted-by":"publisher","first-page":"82217","DOI":"10.18632\/oncotarget.19283","volume":"8","author":"M Wu","year":"2017","unstructured":"Wu M, Guan J, Li C, et al. Aberrantly activated Cox-2 and Wnt signaling interact to maintain cancer stem cells in glioblastoma. Oncotarget. 2017;8:82217\u201330. https:\/\/doi.org\/10.18632\/oncotarget.19283.","journal-title":"Oncotarget."},{"key":"3000_CR67","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1158\/0008-5472.CAN-14-2377","volume":"75","author":"Y Hong","year":"2015","unstructured":"Hong Y, Manoharan I, Suryawanshi A, et al. \u03b2-catenin promotes regulatory T-cell responses in tumors by inducing vitamin A metabolism in dendritic cells. Cancer Res. 2015;75:656\u201365. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2377.","journal-title":"Cancer. Res."},{"key":"3000_CR68","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1158\/1541-7786.MCR-13-0418","volume":"12","author":"Z Liu","year":"2014","unstructured":"Liu Z, Rebowe RE, Wang Z, et al. KIF3a promotes proliferation and invasion via Wnt signaling in advanced prostate cancer. Mol Cancer Res. 2014;12:491\u2013503. https:\/\/doi.org\/10.1158\/1541-7786.MCR-13-0418.","journal-title":"Mol. Cancer. Res."},{"key":"3000_CR69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10238-023-01274-z","volume":"24","author":"K Mortezaee","year":"2024","unstructured":"Mortezaee K. WNT\/\u03b2-catenin regulatory roles on PD-(L)1 and immunotherapy responses. Clin Exp Med. 2024;24:15. https:\/\/doi.org\/10.1007\/s10238-023-01274-z.","journal-title":"Clin. Exp. Med."},{"key":"3000_CR70","doi-asserted-by":"publisher","first-page":"20224","DOI":"10.1073\/pnas.1314239110","volume":"110","author":"J Liu","year":"2013","unstructured":"Liu J, Pan S, Hsieh MH, et al. Targeting wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci USA. 2013;110:20224\u20139. https:\/\/doi.org\/10.1073\/pnas.1314239110.","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"3000_CR71","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1083\/jcb.200806024","volume":"183","author":"S Liebner","year":"2008","unstructured":"Liebner S, Corada M, Bangsow T, et al. Wnt\/\u03b2-catenin signaling controls development of the blood\u2013brain barrier. J Cell Biol. 2008;183:409\u201317. https:\/\/doi.org\/10.1083\/jcb.200806024.","journal-title":"J. Cell. Biol."},{"key":"3000_CR72","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s11060-010-0192-y","volume":"100","author":"F Stockhammer","year":"2010","unstructured":"Stockhammer F, Misch M, Koch A, et al. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. J Neurooncol. 2010;100:407\u201315. https:\/\/doi.org\/10.1007\/s11060-010-0192-y.","journal-title":"J. Neurooncol."},{"key":"3000_CR73","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","volume":"83","author":"WKA Yung","year":"2000","unstructured":"Yung WKA, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588\u201393. https:\/\/doi.org\/10.1054\/bjoc.2000.1316.","journal-title":"Br. J. Cancer."},{"key":"3000_CR74","first-page":"4955","volume":"35","author":"J Kerschbaumer","year":"2015","unstructured":"Kerschbaumer J, Schmidt FA, Grams AE, et al. Dual anti-angiogenic chemotherapy with temozolomide and celecoxib in selected patients with malignant glioma not eligible for standard treatment. Anticancer Res. 2015;35:4955\u201360.","journal-title":"Anticancer. Res."},{"key":"3000_CR75","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3109\/09553002.2010.519423","volume":"87","author":"KA Van Nifterik","year":"2011","unstructured":"Van Nifterik KA, Van Den Berg J, Slotman BJ, Van Rijn J. Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells. Int J Radiat Biol. 2011;87:192\u2013201. https:\/\/doi.org\/10.3109\/09553002.2010.519423.","journal-title":"Int. J. Radiat. Biol."},{"key":"3000_CR76","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.1016\/j.wneu.2018.08.080","volume":"120","author":"SE Navone","year":"2018","unstructured":"Navone SE, Guarnaccia L, Cordiglieri C, et al. Aspirin affects tumor angiogenesis and sensitizes human glioblastoma endothelial cells to temozolomide, bevacizumab, and sunitinib, impairing vascular endothelial growth factor-related signaling. World Neurosurg. 2018;120:e380\u201391. https:\/\/doi.org\/10.1016\/j.wneu.2018.08.080.","journal-title":"World. Neurosurg."},{"key":"3000_CR77","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/cns.12041","volume":"19","author":"Z Shi","year":"2013","unstructured":"Shi Z, Qian X, Liu C, et al. Aspirin-\/ <scp>TMZ<\/scp> -coloaded microspheres exert synergistic antiglioma efficacy via Inhibition of \u03b2-catenin transactivation. CNS Neurosci Ther. 2013;19:98\u2013108. https:\/\/doi.org\/10.1111\/cns.12041.","journal-title":"CNS. Neurosci. Ther."},{"key":"3000_CR78","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13046-018-0926-9","volume":"37","author":"Y Peng","year":"2018","unstructured":"Peng Y, Wang Y, Tang N, et al. Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J Exp Clin Cancer Res. 2018;37:248. https:\/\/doi.org\/10.1186\/s13046-018-0926-9.","journal-title":"J. Exp. Clin. Cancer. Res."},{"key":"3000_CR79","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1479-666X(09)80042-5","volume":"7","author":"DP Toomey","year":"2009","unstructured":"Toomey DP, Murphy JF, Conlon KC. COX-2, VEGF and tumour angiogenesis. Surgeon. 2009;7:174\u201380. https:\/\/doi.org\/10.1016\/S1479-666X(09)80042-5.","journal-title":"Surgeon."},{"key":"3000_CR80","doi-asserted-by":"publisher","first-page":"e0140613","DOI":"10.1371\/journal.pone.0140613","volume":"10","author":"V Leidgens","year":"2015","unstructured":"Leidgens V, Seliger C, Jachnik B, et al. Ibuprofen and diclofenac restrict migration and proliferation of human glioma cells by distinct molecular mechanisms. Plos One. 2015;10:e0140613. https:\/\/doi.org\/10.1371\/journal.pone.0140613.","journal-title":"Plos. One."},{"key":"3000_CR81","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.canlet.2009.02.018","volume":"281","author":"A Bernardi","year":"2009","unstructured":"Bernardi A, Braganhol E, J\u00e4ger E, et al. Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett. 2009;281:53\u201363. https:\/\/doi.org\/10.1016\/j.canlet.2009.02.018.","journal-title":"Cancer. Lett."},{"key":"3000_CR82","doi-asserted-by":"publisher","unstructured":"Bernardi A, Frozza, Hoppe, et al 2013. The antiproliferative effect of indomethacin-loaded lipid-core nanocapsules in glioma cells is mediated by cell cycle regulation, differentiation, and the inhibition of survival pathways. Int. J. Nanomedicine. 711. https:\/\/doi.org\/10.2147\/IJN.S40284","DOI":"10.2147\/IJN.S40284"},{"key":"3000_CR83","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S94467","volume":"11","author":"W-L Lu","year":"2016","unstructured":"Lu W-L, Ju R-J, Zeng F, et al. Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma. Int J Nanomedicine. 2016;11:31. https:\/\/doi.org\/10.2147\/IJN.S94467.","journal-title":"Int. J. Nanomedicine."},{"key":"3000_CR84","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/IJN.S124701","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S. Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells. Int J Nanomedicine. 2018;13:11\u20133. https:\/\/doi.org\/10.2147\/IJN.S124701.","journal-title":"Int. J. Nanomedicine."},{"key":"3000_CR85","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1215\/15228517-2008-005","volume":"10","author":"S Kesari","year":"2008","unstructured":"Kesari S, Schiff D, Henson JW, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol. 2008;10:300\u20138. https:\/\/doi.org\/10.1215\/15228517-2008-005.","journal-title":"Neuro. Oncol."},{"key":"3000_CR86","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1161\/01.CIR.0000025261.58465.62","volume":"106","author":"B Pitt","year":"2002","unstructured":"Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation. 2002;106:167\u20139. https:\/\/doi.org\/10.1161\/01.CIR.0000025261.58465.62.","journal-title":"Circulation."},{"key":"3000_CR87","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0735-1097(01)01749-1","volume":"39","author":"RJ Bing","year":"2002","unstructured":"Bing RJ, Lomnicka M. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J Am Coll Cardiol. 2002;39:521\u20132. https:\/\/doi.org\/10.1016\/S0735-1097(01)01749-1.","journal-title":"J. Am. Coll. Cardiol."},{"key":"3000_CR88","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.108.764530","volume":"117","author":"SD Solomon","year":"2008","unstructured":"Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials. Circulation. 2008;117:2104\u201313. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.764530.","journal-title":"Circulation."},{"key":"3000_CR89","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s40272-022-00514-1","volume":"24","author":"VC Ziesenitz","year":"2022","unstructured":"Ziesenitz VC, Welzel T, van Dyk M, et al. Efficacy and safety of NSAIDs in infants: a comprehensive review of the literature of the past 20 years. Pediatr Drug. 2022;24:603\u201355. https:\/\/doi.org\/10.1007\/s40272-022-00514-1.","journal-title":"Pediatr. Drug."},{"key":"3000_CR90","doi-asserted-by":"publisher","unstructured":"Ralph SJ, Nozuhur S, Moreno-Snchez R, et al 2018. NSAID celecoxib: a potent mitochondrial pro-oxidant cytotoxic agent sensitizing metastatic cancers and cancer stem cells to chemotherapy. J. Cancer. Metastasis. Treat 4 49 https:\/\/doi.org\/10.20517\/2394-4722.2018.42","DOI":"10.20517\/2394-4722.2018.42"},{"key":"3000_CR91","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3390\/antiox14040459","volume":"14","author":"FR Augello","year":"2025","unstructured":"Augello FR, Lombardi F, Ciummo V, et al. COX-2 inhibition in glioblastoma cells counteracts resistance to temozolomide by inducing oxidative stress. Antioxidants. 2025;14:459. https:\/\/doi.org\/10.3390\/antiox14040459.","journal-title":"Antioxidants."}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03000-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03000-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03000-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:02:15Z","timestamp":1763827335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03000-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":91,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3000"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03000-z","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"530"}}